Protionamide
- Generic Name
- Protionamide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C9H12N2S
- CAS Number
- 14222-60-7
- Unique Ingredient Identifier
- 76YOO33643
- Background
Prothionamide has been used in trials studying the treatment of MDR-TB and HIV Infections.
- Indication
本品与其他抗结核药联合，用于经一线药物（如链霉素、异烟肼、利福平和乙胺丁醇）治疗无效者。本品仅对分枝杆菌有效。
- Associated Conditions
- Hansen's Disease, Tuberculosis (TB)
- Associated Therapies
- -
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 186
- Registration Number
- NCT06081361
- Locations
- 🇨🇳
The 8th Medical Center of Chinese Pla General Hospital, Beijing, China
🇨🇳Hebei Chest Hospital, Shijiazhuang, Hebei, China
🇨🇳Harbin Chest Hospital, Harbin, Heilongjiang, China
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2023-01-18
- Lead Sponsor
- Beijing Chest Hospital
- Target Recruit Count
- 212
- Registration Number
- NCT05306223
- Locations
- 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳The Pulmonary Hospital of Fuzhou in Fujian Province（The tuberculosis control and prevention Hospital of Fuzhou in Fujian Province）, Fuzhou, China
🇨🇳The Eighth Medical Center of PLA General Hospital, Beijing, China
The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- IUATLD, Inc
- Target Recruit Count
- 588
- Registration Number
- NCT02409290
- Locations
- 🇪🇹
Armauer Hanssen Research Institute, Addis Ababa, Ethiopia
🇪🇹St. Peter's Tuberculosis Specializes Hospital, Addis Ababa, Ethiopia
🇬🇪JSC National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.